Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6557554 | 0.89 | ALDH1A1 (0.55) | ALDH1A1LMNAHRH3SIGMAR1KDM4E | |
| SCHEMBL10690328 | 0.83 | LMNA (0.80) | ALDH1A1LMNAHRH3SIGMAR1HRH4 | |
| SCHEMBL941871 | 0.82 | KDM4E (0.62) | ALDH1A1HRH3SIGMAR1KDM4ECCR5 | |
| SCHEMBL12625982 | 0.81 | ALDH1A1 (0.59) | ALDH1A1HRH3 | |
| SCHEMBL4703106 | 0.81 | ALDH1A1 (0.61) | ALDH1A1LMNAHRH3KDM4E | |
| SCHEMBL2794745 | 0.81 | TACR1 (0.55) | ALDH1A1HRH3SIGMAR1KDM4E | |
| SCHEMBL29088788 | 0.81 | HRH3 (0.50) | ALDH1A1HRH3SIGMAR1HRH4KDM4E | |
| SCHEMBL8108397 | 0.81 | ALDH1A1 (0.61) | ALDH1A1LMNAHRH3KDM4E | |
| SCHEMBL4591888 | 0.81 | ALDH1A1 (0.59) | ALDH1A1LMNAHRH3KDM4ECCR5 | |
| SCHEMBL758418 | 0.81 | HRH3 (0.50) | HRH3SIGMAR1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552054-B1 | For prophylaxis and therapy of bone diseases and chondropathy | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| US-6531604-B2 | Useful as medicines having an osteogenesis promoting effect and chondrogensis promoting effect. | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-03-11 | — | — | US | disclosed |
| US-20020128308-A1 | Benzothiepine derivatives, their production and use | YASUMA TSUNEO (JP) | 2002-09-12 | — | — | US | disclosed |
| EP-1211251-A1 | CHROMONE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-06-05 | — | — | EP | disclosed |
| US-6355672-B1 | BONE DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| EP-1103552-A1 | BENZOTHIEPIN DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2001-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128308-A1 | Benzothiepine derivatives, their production and use | APP, BMP1, BACE1 | ALDH1A1 3170/4885LMNA 2119/4885HRH3 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.